175 related articles for article (PubMed ID: 34427738)
1. Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin.
Ohya K; Okuyama S; Ogata SY; Maeda K; Yamada K; Ohshima K; Tajima K
Ann Hematol; 2021 Nov; 100(11):2873-2875. PubMed ID: 34427738
[No Abstract] [Full Text] [Related]
2. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
[TBL] [Abstract][Full Text] [Related]
5. [Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].
Calleja A; Bouclet F
Bull Cancer; 2021 Jan; 108(1):12-13. PubMed ID: 33308986
[No Abstract] [Full Text] [Related]
6. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Zinzani PL; Salles G; Moskowitz AJ; Santoro A; Mehta A; Barr PM; Mehta-Shah N; Collins GP; Ansell SM; Brody JD; Domingo-Domenech E; Johnson NA; Cunningham D; Ferrari S; Lisano J; Krajewski J; Wen R; Akyol A; Crowe R; Savage KJ
Blood Adv; 2024 May; 8(10):2400-2404. PubMed ID: 38531062
[No Abstract] [Full Text] [Related]
7. Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.
Nanni L; Pellegrini C; Stefoni V; Argnani L; Cavo M; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e595-e596. PubMed ID: 31543370
[No Abstract] [Full Text] [Related]
8. Brentuximab vedotin in T-cell lymphoma.
Van Der Weyden C; Dickinson M; Whisstock J; Prince HM
Expert Rev Hematol; 2019 Jan; 12(1):5-19. PubMed ID: 30526166
[TBL] [Abstract][Full Text] [Related]
9. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin.
Şahin M; Miskioğlu M; İnanır I; Akar H; Neşe N; Temiz P; Aydoğdu İ
Turk J Haematol; 2021 Feb; 38(1):85-87. PubMed ID: 33504137
[No Abstract] [Full Text] [Related]
11. Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma.
Badri N; Ngamdu KS; Torabi A; Guar S
J Cancer Res Ther; 2020; 16(1):183-185. PubMed ID: 32362635
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia.
Oka S; Ono K; Nohgawa M
Anticancer Drugs; 2020 Jun; 31(5):536-539. PubMed ID: 31934889
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
Nikolaenko L; Nademanee A
Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
[TBL] [Abstract][Full Text] [Related]
14. FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?
Milunović V; Mišura Jakobac K; Kursar M; Mandac Rogulj I; Ostojić Kolonić S
Eur J Haematol; 2019 Sep; 103(3):145-151. PubMed ID: 31166030
[TBL] [Abstract][Full Text] [Related]
15. [Rituximab in the treatment of diffuse large B-cell lymphoma: The CACNA1C subunit of channel Cav1.2 expression linked to certain forms of resistance].
Bouabdallah S; Mariko ML; Besson J; Dellis O
Med Sci (Paris); 2021 Apr; 37(4):406-408. PubMed ID: 33908862
[No Abstract] [Full Text] [Related]
16. Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.
Kanate AS; Kumar A; Dreger P; Dreyling M; Le Gouill S; Corradini P; Bredeson C; Fenske TS; Smith SM; Sureda A; Moskowitz A; Friedberg JW; Inwards DJ; Herrera AF; Kharfan-Dabaja MA; Reddy N; Montoto S; Robinson SP; Abutalib SA; Gisselbrecht C; Vose J; Gopal A; Shadman M; Perales MA; Carpenter P; Savani BN; Hamadani M
JAMA Oncol; 2019 May; 5(5):715-722. PubMed ID: 30816957
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
19. Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
Kumar A; Fraz MA; Usman M; Malik SU; Ijaz A; Durer C; Durer S; Tariq MJ; Khan AY; Qureshi A; Faridi W; Nasar A; Anwer F
Curr Treat Options Oncol; 2018 Sep; 19(10):50. PubMed ID: 30173370
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
